Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal

03:06 EDT 31 Jul 2013 | Reuters

LONDON, July 31 (Reuters) - AstraZeneca took another step to bolster its new drug pipeline on Wednesday by striking a deal with U.S. biotech firm FibroGen potentially worth more than $815 million for rights to an experimental anaemia drug.

Original Article: UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal

NEXT ARTICLE

More From BioPortfolio on "UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story